Aug 31 (Reuters) - Jazz Pharmaceuticals PLC :
* JAZZ PHARMACEUTICALS ANNOUNCES HEALTH CANADA APPROVAL OF SUNOSI FOR EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA
* JAZZ PHARMACEUTICALS PLC - ONCE-DAILY SUNOSI IS APPROVED WITH DOSES OF 75 MG AND 150 MG
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments